Vital Statistics
| Class |
Ticker |
CUSIP |
Fund Number |
| Investor |
PHPIX |
743185-423 |
047 |
| Service |
PHPSX |
743185-415 |
077 |
Inception Date for all share classes is
6/28/2000
NAV
as of
7/24/2008
| Class |
NAV |
% Change |
$ Change |
| Investor |
$8.24 |
-0.24% |
-$0.02 |
| Service |
$7.94 |
-0.25% |
-$0.02 |
At a GlanceThe Pharmaceuticals UltraSector ProFund provides leveraged exposure to the Dow Jones U.S. Pharmaceuticals Index.
ObjectiveSeeks daily investment results, before fees and expenses, that correspond to 150%, of the daily performance of the Dow Jones U.S. Pharmaceuticals Index.
There is no guarantee that any ProFund will achieve its investment objective. Investment return and principal value will vary and shares may be worth more or less at redemption than at original purchase. See the prospectus for more information.
This ProFund routinely employs leveraged investment techniques that magnify gains and losses and result in greater volatility in value.
This ProFund invests in a single industry. Its shares do not represent a complete investment program. As non-diversified and single industry fund, the value of its shares may fluctuate more than shares invested in a broader range of industries and companies.
|
Dow Jones U.S. Pharmaceuticals Index
The Dow Jones U.S. Pharmaceuticals Index measures the performance of the pharmaceuticals industry of the U.S. equity market. Component companies include the makers of prescription drugs such as birth control pills and vaccines, and over-the-counter drugs, such as aspirin and cold remedies, as well as companies engaged in contract drug research. It is not possible to invest directly in an index.
Index (as of
6/30/2008)
|
|
Top 10 Index Companies
| Name |
Weight |
| Johnson & Johnson |
25.58% |
| Pfizer Inc. |
16.75% |
| Abbott Laboratories |
11.44% |
| Merck & Co. Inc. |
11.36% |
| Wyeth |
8.98% |
| Eli Lilly & Co. |
6.27% |
| Bristol-Myers Squibb Co. |
5.67% |
| Schering-Plough Corp. |
4.48% |
| Allergan Inc. |
2.25% |
| Forest Laboratories Inc. |
1.52% |
Total Index Companies
28
Average Index Market Capitalization
25.44 billion
|
|
Fund Statistics
| Limits On Exchanges |
None |
| Minimum Investment |
Individual Investor |
$15,000 |
|
Financial Professionals |
$5,000 |
|
All data, unless otherwise noted, is as of 6/30/2008 and for Investor Class Shares only and is subject to change.
07-00291
Investing in ProFunds involves certain risks, including in all or some cases, leverage, liquidity, concentration, non-diversification, foreign investment, foreign currency, high yield, interest rate, credit, market, correlation, aggressive investment technique and repurchase agreement risks. Moreover, there is no guarantee that any ProFund will achieve its investment objective. These risks can increase volatility and decrease performance. All ProFunds permit active investment strategies which can decrease performance and increase expenses.
|
|